Chinese Journal of Antituberculosis ›› 2019, Vol. 41 ›› Issue (3): 294-301.doi: 10.3969/j.issn.1000-6621.2019.03.010
• Original Articles • Previous Articles Next Articles
Qi LI1(),Xiao-ying JIANG1,Meng-qiu GAO1,Yu-hong LIU1,Kun-yun YANG2,Xiao-hong KAN3,Jian-qin LIANG4,Ming TIAN5,Jin-cheng LIU6,Wen-yu CUI7,Wen LIU8,De-mei YU9,Shou-yong TAN10,Shen-jie TANG1,Yu-qin LIU11,Xuan LIANG12,Li-hua QIU13,Shi-feng SHAO14,Fei GAO15,Li JIE16,Bao-yun CAI1,Jian-ling BU1,Li-ping MA1,Zhi LIU17,Lin XU18,Juan DU19,Min CAO1,Jing-tao GAO1,Wei SHU1,Liang LI1()
Received:
2018-12-20
Online:
2019-03-10
Published:
2019-03-15
Contact:
Qi LI,Liang LI
E-mail:lq0703@hotmail.com;liliang69@hotmail.com
Qi LI,Xiao-ying JIANG,Meng-qiu GAO,Yu-hong LIU,Kun-yun YANG,Xiao-hong KAN,Jian-qin LIANG,Ming TIAN,Jin-cheng LIU,Wen-yu CUI,Wen LIU,De-mei YU,Shou-yong TAN,Shen-jie TANG,Yu-qin LIU,Xuan LIANG,Li-hua QIU,Shi-feng SHAO,Fei GAO,Li JIE,Bao-yun CAI,Jian-ling BU,Li-ping MA,Zhi LIU,Lin XU,Juan DU,Min CAO,Jing-tao GAO,Wei SHU,Liang LI. Effect of 18 months regimen in the treatment of multidrug-resistant pulmonary tuberculosis[J]. Chinese Journal of Antituberculosis, 2019, 41(3): 294-301. doi: 10.3969/j.issn.1000-6621.2019.03.010
Add to citation manager EndNote|Ris|BibTeX
URL: http://www.zgflzz.cn/EN/10.3969/j.issn.1000-6621.2019.03.010
基本资料 | 对照组(166例) | 观察组(515例) | 统计检验值 | P值 |
---|---|---|---|---|
性别[例(构成比,%)] | χ2=0.151 | 0.697 | ||
男 | 112(67.47) | 341(66.21) | ||
女 | 54(32.53) | 174(33.79) | ||
年龄(岁, | 41.34±12.69 | 37.51±12.62 | t=3.402 | 0.001 |
中位病程[月,M(Q1,Q3)] | 24.27(12.10,24.92) | 24.30(15.17,51.45) | Z=3.148 | 0.002 |
耐药种数( | 3.63±1.33 | 3.50±1.39 | t=0.923 | 0.356 |
复治[例(构成比,%)] | 124(74.70) | 365(70.87) | χ2=1.107 | 0.294 |
治疗次数(次, | 1.94±0.85 | 1.78±0.52 | t=1.013 | 0.312 |
空洞 | ||||
例数(率,%) | 112(67.47) | 379(73.59) | χ2=2.014 | 0.156 |
数量(个, | 2.15±1.82 | 2.26±1.93 | t=0.565 | 0.573 |
病变所占肺野数(个, | 3.64±1.79 | 3.89±1.69 | t=1.488 | 0.137 |
体质量指数( | 20.77±3.46 | 20.26±2.99 | t=1.722 | 0.086 |
症状评分(分, | 4.80±1.39 | 4.59±2.88 | t=0.712 | 0.477 |
并发糖尿病[例(并发率,%)] | 5(3.01) | 35(6.80) | χ2=3.251 | 0.071 |
既往核心药物应用[例(使用率,%)] | ||||
Z | 144(86.75) | 443(86.02) | χ2=0.155 | 0.194 |
Am | 41(24.70) | 106(20.58) | χ2=2.825 | 0.244 |
Lfx | 51(30.72) | 121(23.50) | χ2=3.897 | 0.143 |
Mfx | 3(1.81) | 21(4.08) | χ2=2.207 | 0.332 |
Clr | 8(4.82) | 37(7.18) | χ2=1.104 | 0.293 |
方案中使用药物[例(使用率,%)] | ||||
E | 97(58.43) | 360(69.90) | χ2=6.941 | 0.008 |
Pto | 109(65.66) | 342(66.41) | χ2=0.007 | 0.932 |
PAS | 31(18.67) | 205(39.81) | χ2=24.300 | 0.000 |
[1] | World Health Organization. Global tuberculosis report 2018. Geneva: World Health Organization, 2018. |
[2] |
World Health Organization. WHO treatment guidelines for drug-resistant tuberculosis. 2016 update. Geneva: World Health Organization, 2016.
URL pmid: 27748093 |
[3] |
中国防痨协会. 耐药结核病化学治疗指南(2015). 中国防痨杂志, 2015,37(5):421-469.
doi: 10.3969/j.issn.1000-6621.2015.05.001 URL |
[4] |
Ahuja SD, Ashkin D, Avendano M , et al. Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med, 2012,9(8):e1001300.
doi: 10.1371/journal.pmed.1001300 URL pmid: 22952439 |
[5] | 中华人民共和国卫生部. 全国结核病耐药性基线调查报告(2007—2008年). 北京: 人民卫生出版社, 2010. |
[6] | 刘川 . 药物临床试验方法学.北京: 化学工业出版社, 2011: 316. |
[7] |
中华医学会结核病学分会. 肺结核诊断和治疗指南. 中华结核和呼吸杂志, 2001,24(2):70-74.
doi: 10.3760/j:issn:1001-0939.2001.02.002 URL |
[8] | World Health Organization. Guidelines for the programmatic management of drug resistant tuberculosis. Geneva:World Health Organization, 2008. |
[9] |
中国防痨协会. 耐多药结核病化学治疗的意见(试行). 中国防痨杂志, 2003,25(1):4-9.
doi: 10.3969/j.issn.1000-6621.2003.01.003 URL |
[10] | World Health Organization. Definitions and reporting framework for tuberculosis——2013 revision. Geneva: World Health Organization, 2013. |
[11] |
Brigden G, Nyang’wa BT, du Cros P , et al. Principles for designing future regimens for multidrug-resistant tuberculosis. Bull World Health Organ, 2014,92(1):68-74.
doi: 10.2471/BLT.13.122028 URL pmid: 15137531 |
[12] |
Zheng M, Jin H, Fu L , et al. A comparative study on the activities of six combination regimens against multidrug-resistant Mycobacterium tuberculosis infection in BALB/c mice. J Chemother, 2013,25(2):81-86.
doi: 10.1179/1973947812Y.0000000064 URL pmid: 23684355 |
[13] | 郝晓晖, 唐神结, 陈先平 , 等. 耐多药肺结核患者合并呼吸道感染的菌种分布及药敏分析. 中国防痨杂志, 2011,33(2):103-108. |
[14] |
Pang Y, Zhu D, Zheng H , et al. Prevalence and molecular characterization of pyrazinamide resistance among multidrug-resistant Mycobacterium tuberculosis isolates from Southern China. BMC Infect Dis, 2017,17(1):711.
doi: 10.1186/s12879-017-2761-6 URL pmid: 29110640 |
[15] |
Cavalieri SJ, Biehle JR, Sanders WE Jr . Synergistic activities of clarithromycin and antituberculous drugs against multidrug-resistant Mycobacterium tuberculosis. Antimicrob Agents Chemother, 1995,39(7):1542-1545.
doi: 10.1128/AAC.39.7.1542 URL pmid: 162778 |
[16] |
Mor N, Esfandiari A . Synergistic activities of clarithromycin and pyrazinamide against Mycobacterium tuberculosis in human macrophages. Antimicrob Agents Chemother, 1997,41(9):2035-2036.
doi: 10.1097/00001813-199709000-00010 URL pmid: 164062 |
[17] |
Andini N, Nash KA . Intrinsic macrolide resistance of the Mycobacterium tuberculosis complex is inducible. Antimicrob Agents Chemother, 2006,50(7):2560-2562.
doi: 10.1128/AAC.00264-06 URL |
[18] |
Van der Paardt AL, Akkerman OW, Gualano G , et al. Safety and tolerability of clarithromycin in the treatment of multidrug-resistant tuberculosis. Eur Respir J, 2017, 49(3). pii: 1601612.
doi: 10.1183/13993003.01612-2016 URL pmid: 28331034 |
[19] |
Van der Paardt AF, Wilffert B, Akkerman OW , et al. Evaluation of macrolides for possible use against multidrug-resistant Mycobacterium tuberculosis. Eur Respir J, 2015,46(2):444-455.
doi: 10.1183/09031936.00147014 URL pmid: 26022960 |
[20] |
Bolhuis MS, van der Laan T, Kosterink JG , et al. In vitro synergy between linezolid and clarithromycin against Mycobacterium tuberculosis. Eur Respir J, 2014,44(3):808-811.
doi: 10.1183/09031936.00041314 URL |
[21] |
Sotgiu G, Centis R, D’Ambrosio L , et al. Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. Eur Respir J, 2012,40(6):1430-1442.
doi: 10.1183/09031936.00022912 URL pmid: 22496332 |
[22] |
Van Deun A, Maug AK, Salim MA , et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med, 2010,182(5):684-692.
doi: 10.1164/rccm.201001-0077OC URL pmid: 20442432 |
[23] | 李杨, 王飞, 吴琍敏 , 等. 环丝氨酸在耐多药结核病化学治疗中应用价值的探讨. 中国防痨杂志, 2018,40(2):168-172. |
[24] |
王飞, 陈彬, 周琳 , 等. 耐多药肺结核患者抗结核药物所致不良反应发生情况. 中华传染病杂志, 2017,35(2):83-87.
doi: 10.3760/cma.j.issn.1000-6680.2017.02.005 URL |
[25] |
Nathanson E, Gupta R, Huamani P , et al. Adverse events in the treatment of multidrug-resistant tuberculosis: results from the DOTS-Plus initiative. Int J Tuberc Lung Dis, 2004,8(11):1382-1384.
URL pmid: 15137531 |
[26] |
Ahmad N, Ahuja SD, Akkerman OW , et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Lancet, 2018,392(10150):821-834.
doi: 10.1016/S0140-6736(18)31644-1 URL |
[1] | LIU Xiao-li, LEI Li-mei, GUO Zhou-li, HUANG Yin, XU Jing, ZHAO Xia, WANG Yan, FU Li. Study on the relationship of stigma and social support of tuberculosis patients [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 1002-1008. |
[2] | Academic Working Committee of Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis . Expert consensus of clinical application of fixed-dose combination formulations [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 885-893. |
[3] | JIN Hong-jian. The construction of tuberculosis prevention and control service system at county level in China needs to be strengthened urgently —— Comments and suggestions of an old tuberculosis control and prevention worker [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 896-902. |
[4] | ZHANG Can-you, XIA Hui, CHENG Jun. Testing and reporting requirements for Class Ⅱ biosafety cabinet in tuberculosis laboratory [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 903-909. |
[5] | ZHOU Lin, LIU Er-yong, MENG Qing-lin, CHEN Ming-ting, ZHOU Xin-hua, GAO Wei-wei, LIN Ming-gui, XIE Ru-ming. Evaluation of the quality of pulmonary tuberculosis diagnosis after the implementation of the newly revised WS 288-2017 Diagnosis for pulmonary tuberculosis standards [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 910-915. |
[6] | LIU Er-yong, WANG Qian, ZHOU Lin, ZHANG Guo-qin, ZHANG Xiu-lei, MA Yong-cheng, YANG Shu-min, WANG Cui, MENG Qing-lin, CHEN Ming-ting, LIN Ming-gui, TU De-hua.. Analysis of diagnostic quality of pulmonary tuberculosis with negative etiology in some areas of China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 916-920. |
[7] | MENG Qing-lin, LI Jin-lan, LIN Ding-wen, MA Yong-cheng, HOU Shuang-yi, LIU Nian-qiang, ZHOU Lin. Analysis of the awareness about knowledge on the updated TB diagnosis standard among the practitioners in TB control institutions [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 921-925. |
[8] | WANG Qian, ZHOU Lin, LIU Er-yong, ZHAO Yan-lin, LI Tao, CHEN Ming-ting, YANG Li-jia, WANG Jia.. A survey on the diagnostic ability of tuberculosis in the county-level medical institutions in China [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 926-930. |
[9] | LI Ting, HE Jin-ge, SU Qian, LI Jing, LI Yun-kui, GAO Wen-feng, GAO Yuan, YANG Wen. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 931-936. |
[10] | LI Yun-kui, HE Jin-ge, SU Qian, LI Ting, LI Jing, GAO Wen-feng, YANG Wen, MAO Guang-yu. Value of tuberculin test in screening tuberculosis infection in HIV infected/AIDS patients in Butuo County, Sichuan Province [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 937-941. |
[11] | SU Qian, XIA Yong, LU Jia, WANG Dan-xia, HE Jin-ge. Analysis on the epidemiological characteristics of pulmonary tuberculosis among children aged 0-14 in Sichuan Province from 2009 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 942-947. |
[12] | DENG Ya-li, ZHANG Tian-hua, LIU Wei-ping, ZHANG Hong-wei, MA Yu, LI Peng.. Temporal and spatial clustering analysis of pulmonary tuberculosis incidence in Shaanxi Province from 2014 to 2018 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 948-955. |
[13] | DONG Xiao, ZHAO Zhen, LIU Nian-qiang, WANG Sen-lu, CUI Yan. Analysis of the finding characteristics of pulmonary tuberculosis in the elderly population in Xinjiang Uygur Autonomous Region during 2009—2017 [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 956-961. |
[14] | MA Ting-long, HAN Yi, CHENG Xu, LIU Zhi-dong. Clinical observation on treatment effectiveness of transdermal ultrasound-mediated drug delivery combined with oral anti-tuberculosis drug in patients with chest wall tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 968-972. |
[15] | NAN Hai, ZHANG Yun, YANG Xin-ting, DUAN Hong-fei. Meta-analysis on the diagnostic value of GeneXpert MTB/RIF for bone and joint tuberculosis [J]. Chinese Journal of Antituberculosis, 2020, 42(9): 973-980. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||